Multiple Myeloma Treatment Response Assessment from Routine Test Sequences
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for assessing a patient's response to multiple myeloma treatment, such as the International Myeloma Working Group (IMWG) criteria, require comprehensive laboratory measurements that are often incomplete in electronic health records, necessitating a more reliable method using routinely collected data.
Innovation Solution
A computer-implemented method that determines a patient's response by analyzing the results of consecutive tests over time, using predefined algorithms to verify and adjust responses based on subsequent test results, excluding bone marrow biopsies and relying on serum and urine protein measurements.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If comprehensive laboratory measurements (IMWG criteria) are used to assess treatment response, then measurement precision is improved, but device complexity and data collection requirements increase
Solution Approach 1:
The patent extracts and utilizes only the essential components from the IMWG criteria that are routinely collected in electronic health records, specifically serum M-protein, urine M-protein, and free light chain measurements. By taking out only the necessary measurements that are already part of routine practice, the method maintains adequate response assessment accuracy while eliminating the complexity of requiring bone marrow biopsies and other specialized tests.
Solution Approach 2:
The patent applies partial action by using a subset of the full IMWG criteria rather than all required measurements. Specifically, it uses serum M-protein, urine M-protein, and free light chain measurements (which are routinely collected) instead of requiring all IMWG parameters including bone marrow biopsies. This partial approach provides sufficient response assessment while reducing data collection complexity.
2Reliability
If all IMWG criteria measurements are collected, then reliability of response assessment is improved, but loss of time and resource consumption increase
Solution Approach 1:
The patent extracts only the measurements that are already part of routine clinical practice in electronic health records, specifically serum M-protein, urine M-protein, and free light chain measurements. By taking out only these routinely collected parameters, the method maintains reliable response assessment without the time cost of collecting additional specialized data like bone marrow biopsies.
Solution Approach 2:
The method leverages the existing routine data collection processes in clinical practice, where serum M-protein, urine M-protein, and free light chain measurements are already being collected as standard of care. This self-service approach utilizes existing infrastructure and time investment in routine monitoring, eliminating the need for additional specialized data collection efforts.
3Ease of operation
If routine routinely collected data is used, then ease of operation is improved, but measurement precision deteriorates
Solution Approach 1:
The patent identifies measurements that serve multiple functions: serum M-protein, urine M-protein, and free light chain measurements are routinely collected for monitoring treatment response in multiple myeloma. By using these universally collected parameters, the method achieves both ease of operation (using existing routine data) and adequate measurement precision (through multi-parameter assessment combining serum, urine, and free light chain data).
Solution Approach 2:
The patent merges multiple routinely collected measurements (serum M-protein, urine M-protein, and free light chain measurements) into a comprehensive response assessment framework. By combining these multiple parameters, the method achieves sufficient measurement precision while maintaining ease of operation, as all parameters are already part of routine clinical data collection.
Data Source
AI summary
The present disclosure relates to a computer-implemented method of a computer-implemented method of determining a patient's response to a treatment in multiple myeloma. The method comprises:providing results of a series of predefined consecutive tests on the patient,determining a response at time t as a function of a test result of the time t and a subsequent test result of a time t+1.